bioMérieux will be awarded up to EUR54.5 million by France's Agence de l'Innovation Industrielle for molecular biology research
The ADNA program aims to develop personalized medical solutions for cancer, infectious diseases and rare genetic diseases. Four strategically aligned partners, bioMérieux, Généthon, GenoSafe® and Transgene, have teamed up to meet the challenge. An initial partnership between bioMérieux and Ipsen in oncology research has given the project an additional boost.
Over the next ten years, the assistance provided by the agency will help finance programs designed to:
* Find, identify and validate biomarkers. The identification of biomarkers shall help scientists to develop diagnostic tests for earlier disease detection, determine appropriate treatments and monitor treatment response in patients.
* Develop new molecular diagnostic platforms to perform high-value-added analyses of infectious diseases and certain types of cancer.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.